Bio-XCell Biotechnology Park

www.bio-xcell.my

Bio-XCell a biotechnology park & ecosystem dedicated to healthcare and industrial biotechnology developed by Malaysian Bio-XCell, is a joint venture company formed between Malaysia Biotechnology Corp and property developer UEM Land in 2009

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

BIO-TECHNE AND CYGNUS TECHNOLOGIES PRESENT PLEX HEK 293 HCP 3G IMMUNOASSAY

Bio-Techne Corporation | April 13, 2022

news image

Bio-Techne Corporation launched 3G assay for automated process impurity assessment on the EllaTM immunoassay platform ( NASDAQ: TECH ) and Cygnus Technologies, a division of Maravai LifeSciences ( NASDAQ: MRVI ). In cell and gene therapy applications, the purification of viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. To guarantee HCP impurity clearance is performed in compliance with regulatory criteria, accurate quan...

Read More

MedTech, Industry Outlook

MISSION BIO LAUNCHES TAPESTRI V3 TO RAPIDLY ACCELERATE RARE CELL DETECTION APPLICATIONS FOR TRANSLATIONAL RESEARCH AND PRECISION THERAPEUTICS

PRNewswire | June 01, 2023

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications. With Tapestri® v3 chemistry, researchers can discover tiny numbers of single cells that, until now, easily escaped detection and influenced disease in invisible ways. At the same time, drug developers can use the new capabiliti...

Read More

Cell and Gene Therapy, Diagnostics

VERTEX AND CRISPR THERAPEUTICS ANNOUNCE A LICENSING AGREEMENT TO HASTEN THE DEVELOPMENT OF HYPOIMMUNE CELL THERAPIES FOR TYPE 1 DIABETES

Businesswire | March 28, 2023

news image

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). “We have multiple programs in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune program, in preclinic...

Read More

MedTech, Medical

NANOSTRING PLATFORMS ADVANCE GROUNDBREAKING STUDIES OF IMMUNE RESPONSE IN PIG-TO-HUMAN ORGAN TRANSPLANTS

Businesswire | August 22, 2023

news image

NanoString Technologies, Inc. a leading provider of life science tools for discovery and translational research, The seminal research led by Alexander Loupy, MD, Ph.D., in cooperation with a global medical team, unravels the complex molecular characteristics of antibody-mediated rejection following the first and second-ever pig-to-human kidney transplants that occurred in 2021 at NYU Langone Transplant Institute. In an accompanying Lancet commentary, scientists praised the team ...

Read More
news image

Medical

BIO-TECHNE AND CYGNUS TECHNOLOGIES PRESENT PLEX HEK 293 HCP 3G IMMUNOASSAY

Bio-Techne Corporation | April 13, 2022

Bio-Techne Corporation launched 3G assay for automated process impurity assessment on the EllaTM immunoassay platform ( NASDAQ: TECH ) and Cygnus Technologies, a division of Maravai LifeSciences ( NASDAQ: MRVI ). In cell and gene therapy applications, the purification of viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. To guarantee HCP impurity clearance is performed in compliance with regulatory criteria, accurate quan...

Read More
news image

MedTech, Industry Outlook

MISSION BIO LAUNCHES TAPESTRI V3 TO RAPIDLY ACCELERATE RARE CELL DETECTION APPLICATIONS FOR TRANSLATIONAL RESEARCH AND PRECISION THERAPEUTICS

PRNewswire | June 01, 2023

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications. With Tapestri® v3 chemistry, researchers can discover tiny numbers of single cells that, until now, easily escaped detection and influenced disease in invisible ways. At the same time, drug developers can use the new capabiliti...

Read More
news image

Cell and Gene Therapy, Diagnostics

VERTEX AND CRISPR THERAPEUTICS ANNOUNCE A LICENSING AGREEMENT TO HASTEN THE DEVELOPMENT OF HYPOIMMUNE CELL THERAPIES FOR TYPE 1 DIABETES

Businesswire | March 28, 2023

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). “We have multiple programs in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune program, in preclinic...

Read More
news image

MedTech, Medical

NANOSTRING PLATFORMS ADVANCE GROUNDBREAKING STUDIES OF IMMUNE RESPONSE IN PIG-TO-HUMAN ORGAN TRANSPLANTS

Businesswire | August 22, 2023

NanoString Technologies, Inc. a leading provider of life science tools for discovery and translational research, The seminal research led by Alexander Loupy, MD, Ph.D., in cooperation with a global medical team, unravels the complex molecular characteristics of antibody-mediated rejection following the first and second-ever pig-to-human kidney transplants that occurred in 2021 at NYU Langone Transplant Institute. In an accompanying Lancet commentary, scientists praised the team ...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us